Ramucirumab is a treatment used for patients with advanced gastric cancer or gastro-oesophageal cancer who have progressed after prior treatment with certain types of chemotherapies. Ramucirumab acts by stopping tumour growth by slowing formation of new blood vessels and the blood supply that feeds tumours. Ramucirumab is being developed to be given in combination with other chemotherapies (capecitabine and cisplatin) to treat unresectable, locally advanced or metastatic gastric cancer of gastro-oesophageal junction which are HER2-negative.
Ramucirumab (Cyramza) + capecitabine or 5-FU + cisplatin for gastric cancer of GOJ – treatment naive for palliative chemotherapy
Interventions:
5-Fluorouracil
, Capecitabine (Xeloda)
, Cisplatin (Platinol)
, Ramucirumab (Cyramza)
Indications:
Gastro-oesophageal junction cancer
Therapeutic Areas:
Gastrointestinal Cancer
Year:
2017